"Cognitively normal older adults with evidence of early brain changes typical of Alzheimer's disease fell more often than did their peers without these brain changes, a new study reported online in Neurology. The results suggest that decl"...
Overdose with Exelon Patch has been reported in the postmarketing setting [see WARNINGS AND PRECAUTIONS]. Overdoses have occurred from application of more than one patch at one time and not removing the previous day's patch before applying a new patch. The symptoms reported in these overdose cases are similar to those seen in cases of overdose associated with rivastigmine oral formulations.
Because strategies for the management of overdose are continually evolving, it is advisable to contact a Poison Control Center to determine the latest recommendations for the management of an overdose of any drug. As rivastigmine has a plasma half-life of about 3.4 hours after patch administration and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose the patch should be immediately removed and no further patch should be applied for the next 24 hours.
As in any case of overdose, general supportive measures should be utilized. Overdosage with cholinesterase inhibitors can result in cholinergic crisis characterized by severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Atypical responses in blood pressure and heart rate have been reported with other drugs that increase cholinergic activity when coadministered with quaternary anticholinergics such as glycopyrrolate. Due to the short plasma elimination half-life of rivastigmine after patch administration, dialysis (hemodialysis, peritoneal dialysis, or hemofiltration) would not be clinically indicated in the event of an overdose.
In overdose accompanied by severe nausea and vomiting, the use of antiemetics should be considered.
Exelon Patch (rivastigmine transdermal system) is contraindicated in patients with:
- known hypersensitivity to rivastigmine, other carbamate derivatives, or other components of the formulation [see DESCRIPTION].
- previous history of application site reactions with rivastigmine transdermal patch suggestive of allergic contact dermatitis [see WARNINGS AND PRECAUTIONS].
Isolated cases of generalized skin reactions have been described in postmarketing experience [see ADVERSE REACTIONS].
Last reviewed on RxList: 7/30/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Exelon Patch Information
Exelon Patch - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.